GSK’s new hepatology candidate puts collaboration work in focus
GSK (LSE:GSK) moved a partnered hepatology drug candidate into its development pipeline after work with Wave Life Sciences’ SpiNA GalNAc siRNA platform, triggering a $12 million milestone payment and renewed attention on collaboration driven R&D.
At a share price of £17.66, GSK has seen the 90 day share price return fall 10.8% and the 30 day share price return decline 4.4%, even though total shareholder return over five years is 52.5%, so long term holders have still been rewarded.
Fresh R&D headlines, including the new hepatology candidate with Wave and extended tuberculosis research funding with AN2 Therapeutics backed by the Gates Foundation, plus positive data from the CROWN HIV study, arrive alongside that softer recent share price trend and may influence how investors weigh future growth prospects and clinical execution risk.
Scan beyond GSK and evaluate other large drug developers that are relying on partnerships and licensing deals through the curated 4 high quality undiscovered gems in the sector.
Recent R&D momentum has not stopped GSK’s share price from drifting. The next step is working out whether that mix of pipeline promise and softer recent returns still tilts the risk reward toward buyers or patience.
Most Popular Narrative: 18% Undervalued
Against GSK’s last close at £17.66, the most followed narrative pegs fair value at £21.61, which implies a sizeable valuation gap based on updated margin and growth assumptions.
Strong volume growth in key high-margin areas like oncology (Jemperli, Blenrep), immunology (Benlysta, Nucala, depemokimab), and HIV (long-acting injectables) is cited as evidence of GSK's ability to capture premium pricing and leverage long-term trends toward innovative, biologic, and personalized therapies, which is viewed as supportive of future earnings and potential margin expansion as these portfolios scale. Strategic R&D investments and business development activity (multiple Phase III starts, advanced modality deals, new manufacturing capacity, and collaborations such as with Hengrui) are described as accelerating pipeline momentum, with expectations for meaningful late-stage readouts and new launches through 2026 and beyond, increasing perceived visibility and durability of future revenue growth.
See why 208 investors see GSK as 18% undervalued.
Result: Fair Value of £21.61 (UNDERVALUED)
Still, if Zantac related cash outflows stay heavy or key HIV and respiratory patents roll off without enough replacement products, the GSK narrative could change quickly.
Find out about the key risks to this GSK narrative.
Next Steps
Plenty in the GSK story points in different directions, so it helps to move fast, review the same data, and pressure test your own stance using the 4 key rewards and 3 important warning signs.
Looking for more GSK-sized investment ideas?
If GSK has your attention, consider broadening your watchlist and testing your thinking against other opportunities before the next round of catalysts hits.
- Target potential upside with a curated pool of quality opportunities by scanning the 6 high quality undervalued stocks.
- Focus on stability to help manage downside risk, starting with a 4 resilient stocks with low risk scores that aims to keep wild swings in check.
- Prioritize financial resilience and steady fundamentals using the list of solid balance sheet and fundamentals (9 results) to spot businesses designed to endure rough patches.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com